The management team at Compendia Bioscience is comprised of true leaders. Each person brings a unique perspective to the table, from the entrepreneur to the scientist. They are forward-thinking, lead by example, ask thoughtful questions, debate issues with vigor, and embrace ideas from the team.
They unite for the company's mission — to cure cancer with genomic data.
Daniel R. Rhodes, Ph.D.
Co-Founder & CEO
Dr. Daniel Rhodes has a 10-year track record in cancer genomics and informatics with more than 30 papers published in peer-reviewed journals. He co-founded Compendia Bioscience with Dr. Arul Chinnaiyan in 2006 with the intent to make Oncomine commercially available. He has lead the company to provide solutions to most large oncology drug development companies, to launch a partnership to develop cancer diagnostics, and to pioneer patient treatment decision support through genomic analysis.
Dr. Rhodes received a Ph.D. in Bioinformatics from the University of Michigan, contributing to several important advances in the field, including the seminal discovery ofrecurrent gene fusions in prostate cancer. Dr. Rhodes led the original development of Oncomine™ and the Oncomine Concepts Map in addition to several novel bioinformatics methods, including Meta-analysis of Microarrays and Cancer Outlier Profile Analysis (COPA).
Dr. Rhodes has received several awards for his work including the Harold Weintraub Award and the Team Science Award from the AACR. Dr. Rhodes maintains a part-time faculty research position at the University of Michigan Center for Translational Pathology.
Arul Chinnaiyan, M.D., Ph.D.
Dr. Arul Chinnaiyan is a Howard Hughes Medical Institute Investigator, the S.P. Hicks Endowed Professor of Pathology and Professor of Pathology and Urology at the University of Michigan Medical School, and is also a member of the Comprehensive Cancer Center and Bioinformatics Program
Dr. Chinnaiyan is recognized as a world leader in cancer genomics and has authored more than 225 peer-reviewed publications including in high-impact journals such as Nature, Science, Cell, JAMA and the New England Journal of Medicine.
In 2006, he co-founded Compendia Bioscience with Dr. Daniel Rhodes.
In 2007, he was named the Director of a new initiative at the University called the Michigan Center for Translational Pathology (MCTP), the goal of which is to develop new molecular tests and therapeutics for human disease with a primary focus on cancer. Dr. Chinnaiyan is a board certified Clinical Pathologist and currently serves as Director of the Division of Pathology Research Informatics and Director of Cancer Bioinformatics.
Dr. Chinnaiyan has received a number of awards including the Basic Science Research Award awarded by the University of Michigan Medical School Dean's Office, the AMGEN Outstanding Investigator Award, the Pew Biomedical Scholar Award, the Burroughs Welcome Foundation Award in Clinical Translational Research, the 2006 Benjamin Castleman Award, the 2007 Ramzi Cotran Young Investigator Award, and the 28th annual American Association for Cancer Research Award for Outstanding Achievement in Cancer Research (2008). He also lead the group of researchers for the inaugural 2007 American Association for Cancer Research "Team Science" Award for their discovery of gene fusions in prostate cancer.
VP Scientific Applications
Director of Translational Medicine
Chief Business Officer
Manager, Product Informatics
Chief FINANCIAL Officer
Director of Translational Medicine
Manager, Scientific Content
Chief Technology Officer